This invention relates to a solid veterinary formulation and a method for its oral administration to an animal, especially cats or dogs, to remove fluid overload in the animal by using a mixture of a water-absorbing polymer and solid fat, optionally having one or more supplemental ingredients. The fluid overload is caused by congestive heart failure or renal disease. The polymer is capable of absorbing at least 10 times its weight in physiological saline. The polymer and other waste materials are excreted in the feces.

This invention relates to a solid veterinary formulation and a method for its oral administration to an animal, especially cats or dogs, to remove fluid overload in the animal by using a mixture of a water-absorbing polymer and solid fat, optionally having one or more supplemental ingredients. The fluid overload is caused by congestive heart failure or renal disease. The polymer is capable of absorbing at least 10 times its weight in physiological saline. The polymer and other waste materials are excreted in the feces.

A nutritional supplement for increasing cognitive functioning. The supplement includes a flavonoid such as luteolin and a labdane diterpene such as forskolin. The supplement can also include one or any combination of L-phenylalanine, L-carnitine, acetyl-L-carnitine, and vitamin B6 . Artichoke extract can be used as a source of luteolin. Methods of using the nutritional supplements to increase cognitive functioning are also included.

A nutritional supplement for increasing cognitive functioning. The supplement includes a flavonoid such as luteolin and a labdane diterpene such as forskolin. The supplement can also include one or any combination of L-phenylalanine, L-carnitine, acetyl-L-carnitine, and vitamin B6 . Artichoke extract can be used as a source of luteolin. Methods of using the nutritional supplements to increase cognitive functioning are also included.

The present invention relates to a pharmaceutical composition for preventing or treating somnipathy including phloroglucinol as an active ingredient and a health functional food composition for ameliorating somnipathy including phloroglucinol as an active ingredient. The pharmaceutical composition and the health functional food composition according to the present invention rapidly and reliably induce and maintain sleep, prevent repeated awakenings, unalter physiological sleep architecture, are particularly devoid of residual sedative effects, which could impair daytime functioning and cognitive performance, do not cause tolerance to a conventional agonist at the benzodiazepine binding site of the GABA-A receptor despite long-term administration, and do not cause side effects of a conventional agonist at the benzodiazepine binding site of the GABA-A receptor. The present invention also relates to a pharmaceutical composition for suppressing tolerance to or alleviating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor including phloroglucinol as an active ingredient and a health functional food composition for suppressing tolerance to or ameliorating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor including phloroglucinol as an active ingredient. The pharmaceutical composition and the health functional food composition according to the present invention can alleviate side effects of the agonist or can suppress tolerance to the agonist resulting from long-term administration. The present invention also relates to a pharmaceutical composition for preventing or treating somnipathy including phloroglucinol and an agonist at the benzodiazepine binding site of the GABA-A receptor as active ingredients. The pharmaceutical composition of the present invention uses a reduced amount of the agonist, which may increase the amount of sleep but degrade the quality of sleep to cause various side effects, to alleviate side effects of the agonist or suppress tolerance to the agonist resulting from long-term administration.

The present invention relates to a pharmaceutical composition for preventing or treating somnipathy including phloroglucinol as an active ingredient and a health functional food composition for ameliorating somnipathy including phloroglucinol as an active ingredient. The pharmaceutical composition and the health functional food composition according to the present invention rapidly and reliably induce and maintain sleep, prevent repeated awakenings, unalter physiological sleep architecture, are particularly devoid of residual sedative effects, which could impair daytime functioning and cognitive performance, do not cause tolerance to a conventional agonist at the benzodiazepine binding site of the GABA-A receptor despite long-term administration, and do not cause side effects of a conventional agonist at the benzodiazepine binding site of the GABA-A receptor. The present invention also relates to a pharmaceutical composition for suppressing tolerance to or alleviating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor including phloroglucinol as an active ingredient and a health functional food composition for suppressing tolerance to or ameliorating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor including phloroglucinol as an active ingredient. The pharmaceutical composition and the health functional food composition according to the present invention can alleviate side effects of the agonist or can suppress tolerance to the agonist resulting from long-term administration. The present invention also relates to a pharmaceutical composition for preventing or treating somnipathy including phloroglucinol and an agonist at the benzodiazepine binding site of the GABA-A receptor as active ingredients. The pharmaceutical composition of the present invention uses a reduced amount of the agonist, which may increase the amount of sleep but degrade the quality of sleep to cause various side effects, to alleviate side effects of the agonist or suppress tolerance to the agonist resulting from long-term administration.

The present invention comprises compositions having a.) at least one acetyltransferase EP300 inhibitor-substance, such as chemically pure spermidine or spermidine-rich wheat germ extract, and optionally b.) at least one nrf2 activator-substance, such as cocoa flavonoids. In use, a user typically adds said compositions to food during the day, and then consumes compositions with food. Typically, such additions are scheduled to occur regularly on consecutive days, for months and over years, such as edible bits of sprinkles-configuration added to meals and snacks, or other configurations as herein disclosed. Such compositions are typically consumed by user in divided doses each day, as disclosed herein.

The present invention comprises compositions having a.) at least one acetyltransferase EP300 inhibitor-substance, such as chemically pure spermidine or spermidine-rich wheat germ extract, and optionally b.) at least one nrf2 activator-substance, such as cocoa flavonoids. In use, a user typically adds said compositions to food during the day, and then consumes compositions with food. Typically, such additions are scheduled to occur regularly on consecutive days, for months and over years, such as edible bits of sprinkles-configuration added to meals and snacks, or other configurations as herein disclosed. Such compositions are typically consumed by user in divided doses each day, as disclosed herein.

Provided are a pharmaceutical composition for preventing or treating metabolic diseases and a health food for alleviating metabolic diseases, each of which the pharmaceutical composition and the health food includes, a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers, wherein such a compound exhibits effects of inhibiting fat content or differentiation of an adipocyte, inhibiting activity of a carbohydrate metabolism enzyme, protecting pancreas, inhibiting blood sugar, and promoting insulin secretion, and thus can be favorably utilized in the treatment of metabolic diseases, such as obesity, diabetes, and hyperlipidemia.

Provided are a pharmaceutical composition for preventing or treating metabolic diseases and a health food for alleviating metabolic diseases, each of which the pharmaceutical composition and the health food includes, a stereoisomer of isonitramine or a derivative thereof, or a racemic mixture of the stereoisomers, wherein such a compound exhibits effects of inhibiting fat content or differentiation of an adipocyte, inhibiting activity of a carbohydrate metabolism enzyme, protecting pancreas, inhibiting blood sugar, and promoting insulin secretion, and thus can be favorably utilized in the treatment of metabolic diseases, such as obesity, diabetes, and hyperlipidemia.